PROQR THERAPEUTICS EO-04 (0PQ) — Working Capital to Net Assets Ratio
PROQR THERAPEUTICS EO-04 (0PQ) has a Working Capital to Net Assets ratio of 137.1% as of December 2025. Working capital of €67.69 Million (current assets of €100.13 Million minus current liabilities of €32.44 Million) is measured against net assets of €49.37 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See 0PQ free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
PROQR THERAPEUTICS EO-04 Working Capital to Net Assets (2021–2025)
This chart shows how PROQR THERAPEUTICS EO-04's Working Capital to Net Assets ratio has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the ratio stands at 137.1%, reflecting working capital of €67.69 Million against net assets of €49.37 Million EUR. See 0PQ defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for PROQR THERAPEUTICS EO-04 (2021–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for PROQR THERAPEUTICS EO-04 from 2021 to 2025, covering 5 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 0PQ stock market capitalisation.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 137.1% | €67.69 Million | €49.37 Million | €100.13 Million | €32.44 Million | ▲ +7.3 pp |
| 2024 | 129.8% | €114.94 Million | €88.56 Million | €153.84 Million | €38.90 Million | ▼ -79.9 pp |
| 2023 | 209.7% | €86.78 Million | €41.39 Million | €120.99 Million | €34.20 Million | ▲ +9.5 pp |
| 2022 | 200.2% | €133.47 Million | €66.68 Million | €154.46 Million | €20.99 Million | ▲ +55.4 pp |
| 2021 | 144.7% | €163.89 Million | €113.23 Million | €191.48 Million | €27.60 Million | — |